Rahul Lakhotia, M.D.

Trials

Studies that name Rahul Lakhotia, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:47 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT05211336 · Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

  National Cancer Institute (NCI) · active not recruiting · Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS · principal investigator
• Ph2
  NCT03964090 · Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

  National Cancer Institute (NCI) · active not recruiting · Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma · principal investigator
• N/A
  NCT03190928 · Clonal Evolution in Follicular Lymphoma

  National Cancer Institute (NCI) · recruiting · Follicular Lymphoma · principal investigator
• Ph1
  NCT02203526 · Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  National Cancer Institute (NCI) · active not recruiting · Primary Central Nervous System Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.